Philippe Armand, M.D.,Ph.D.
Co-Author
This page shows the publications co-authored by Philippe Armand and Reid Merryman.
Connection Strength
3.316
-
Immune Checkpoint Blockade and Hematopoietic Stem Cell Transplant. Curr Hematol Malig Rep. 2017 02; 12(1):44-50.
Score: 0.732
-
Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. Blood. 2017 03 09; 129(10):1380-1388.
Score: 0.729
-
Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. Blood Adv. 2021 03 23; 5(6):1648-1659.
Score: 0.244
-
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia. 2021 Mar 03.
Score: 0.243
-
Immune and Cell Therapy in Non-Hodgkin Lymphoma. Cancer J. 2020 May/Jun; 26(3):269-277.
Score: 0.229
-
Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. Blood Adv. 2020 03 10; 4(5):858-867.
Score: 0.227
-
PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood. 2019 07 04; 134(1):22-29.
Score: 0.213
-
Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma. Blood Adv. 2017 Dec 12; 1(26):2643-2654.
Score: 0.194
-
Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. J Clin Oncol. 2017 Jan; 35(1):24-31.
Score: 0.180
-
A prospective study of minimal residual disease in patients with diffuse large B-cell lymphoma using an Ig-NGS assay. Leuk Lymphoma. 2021 02; 62(2):478-481.
Score: 0.060
-
Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy. Br J Haematol. 2020 10; 191(1):44-51.
Score: 0.057
-
PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation. Blood Adv. 2020 01 14; 4(1):122-126.
Score: 0.056
-
Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL). Blood. 2019 Nov 13; 134(Supplement_1):32.
Score: 0.055
-
Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil. Blood. 2018 07 05; 132(1):9-16.
Score: 0.050
-
PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood. 2017 07 13; 130(2):221-228.
Score: 0.047
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.